JLE

Epileptic Disorders

MENU

Transient lesions of the splenium of the corpus callosum following rapid withdrawal of levetiracetam Volume 19, issue 3, September 2017

  • [Ari et al., 2015] Ari H., Kahraman F., Acaban M.B. The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia. Turk Kardiyol Dern Ars. 2015;43:284-287. 3
  • [Honda et al., 2006] Honda K., Nishimiya J., Sato H. Transient splenial lesion of the corpus callosum after acute withdrawal of antiepileptic drug: a case report. Magn Reson Med Sci. 2006;5:211-215. 4
  • [Jin et al., 2016] Jin H., Li W., Dong C., Ma L., Wu J., Zhao W. Effects of doses of levetiracetam on aquaporin 4 expression in rats with brain edema following fluid percussion injury. Med Sci Monit. 2016;22:678-686.
  • [Kim et al., 1999] Kim S.S., Chang K.H., Kim S.T. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxity? AJNR Am J Neuroradiol. 1999;20:125-129.
  • [Krause et al., 1983] Krause K.H., Rascher W., Berlit P. Plasma arginine vasopressin concentrations in epileptics under monotherapy. J Neurol. 1983;230:193-196.
  • [Mirsattari et al., 2003] Mirsattari S.M., Lee D.H., Jones M.W., Blume W.T. Transient lesion in the splenium of the corpus callosum in an epileptic patient. Neurology. 2003;60:1838-1841.
  • [Nasrallah and Silver, 2005] Nasrallah K., Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005;46:972-973. 6
  • [Nelles et al., 2006] Nelles M., Bien C.G., Kurthen M., von Falkenhausen M., Urbach H. Transient splenium lesions in presurgical epilepsy patients: incidence and pathogenesis. Neuroradiology. 2006;48:443-448.
  • [Wright et al., 2013] Wright C., Downing J., Mungall D. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.
  • [Yogi and Murayama, 2010] Yogi A., Murayama S. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion; MERS. Okinawa Ihou. 2010;46:1.